Stock Events

Stock Events

Protara Therapeutics 

$4.11
41
+$0.00+0% 17:15 Today

Statistics

Day High
4.22
Day Low
4.06
52W High
7.82
52W Low
2.97
Volume
2,775,429
Avg. Volume
-
Mkt Cap
231M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.57
-0.47
-0.38
-0.29
Expected EPS
-0.325714
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-57.44MNet Income

Analyst Ratings

26.50Average Price Target
The highest estimate is 27.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TARA. It's not an investment recommendation.
NVIDIA
13
NVDA
AMD
9
AMD
Microsoft
8
MSFT
Palantir Technologies
8
PLTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences operates in similar therapeutic areas, including oncology, which competes with Protara's cancer-focused therapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol Myers Squibb offers a range of oncology treatments that directly compete with Protara's cancer drug pipeline.
Merck
MRK
Mkt Cap319.99B
Merck is known for its strong presence in the oncology market, competing with Protara's cancer therapies.
AMGEN
AMGN
Mkt Cap201.93B
Amgen focuses on innovative treatments in areas like oncology, posing competition to Protara's therapeutic approaches.
Pfizer
PFE
Mkt Cap138.61B
Pfizer has a broad portfolio of oncology drugs that compete with Protara's developments in cancer treatment.
Novartis
NVS
Mkt Cap305.1B
Novartis is a leading pharmaceutical company with a strong emphasis on oncology, competing with Protara's cancer therapies.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie has a growing oncology segment that competes with Protara's focus on cancer therapeutics.
Roche
RHHBY
Mkt Cap341.62B
Roche Holding AG, through its Genentech subsidiary, competes in the oncology space, directly challenging Protara's market.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca has a significant presence in oncology, with a portfolio that competes with Protara's cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals, known for its innovative biotechnology, competes in the development of cancer therapies similar to Protara's focus.

About

Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Show more...
CEO
Mr. Jesse Shefferman
Employees
28
Country
United States
ISIN
US74365U1079

Listings

XNAS
US
TARA
STU
DE
1KPA.STU
MU
DE
1KPA.MU
F
DE
1KPA.F

0 Comments

Share your thoughts

FAQ

What is Protara Therapeutics stock price today?▼
The current price of TARA is $4.11 USD — it has increased by +0% in the past 24 hours. Watch Protara Therapeutics stock price performance more closely on the chart.
What is Protara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Protara Therapeutics stocks are traded under the ticker TARA.
Is Protara Therapeutics stock price growing?▼
TARA stock has risen by +0.74% compared to the previous week, the month change is a +3.02% rise, over the last year Protara Therapeutics has showed a +27.02% increase.
What is Protara Therapeutics market cap?▼
Today Protara Therapeutics has the market capitalization of 231M
When is the next Protara Therapeutics earnings date?▼
Protara Therapeutics is going to release the next earnings report on July 30, 2026.
What were Protara Therapeutics earnings last quarter?▼
TARA earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.37 USD resulting in a +15.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Protara Therapeutics revenue for the last year?▼
Protara Therapeutics revenue for the last year amounts to 0 USD.
What is Protara Therapeutics net income for the last year?▼
TARA net income for the last year is -57.44M USD.
How many employees does Protara Therapeutics have?▼
As of July 09, 2026, the company has 28 employees.
In which sector is Protara Therapeutics located?▼
Protara Therapeutics operates in the Health & Wellness sector.
When did Protara Therapeutics complete a stock split?▼
The last stock split for Protara Therapeutics was on January 10, 2020 with a ratio of 1:40.
Where is Protara Therapeutics headquartered?▼
Protara Therapeutics is headquartered in New York, United States.